Search research articles
Contact Us
Filters
Showing results (231-240 of 248) with videos related to
Page
of 25
Sort By:
ESMO Open
|
April 19, 2024
A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations
J Rodon, E Rodriguez, M L Maitland, et al.
Journal of Medicinal Chemistry
|
November 14, 1997
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity
D M Benbrook, M M Madler, L W Spruce, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 18, 2017
Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer
Efrat Dotan, Steven J Cohen, Alexander N Starodub, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 29, 2009
NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors
Orlo H Clark, Al B Benson, Jordan D Berlin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 16, 2022
Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma
Martin Schuler, Lisa Zimmer, Kevin B Kim, et al.
The Oncologist
|
March 19, 2017
Academic Cancer Center Phase I Program Development
Arthur E Frankel, Keith T Flaherty, George J Weiner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 6, 2009
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008
C Verslype, E Van Cutsem, M Dicato, et al.
The Oncologist
|
May 7, 2014
Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel
Douglas B Johnson, Kimberly H Dahlman, Jared Knol, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 20, 2021
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
A Bardia, W A Messersmith, E A Kio, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 30, 2010
Pancreatic adenocarcinoma
Margaret A Tempero, J Pablo Arnoletti, Stephen Behrman, et al.
Page
of 25
Search research articles
Search
Showing results (231-240 of 248) with videos related to
Sort By:
Page
of 25
ESMO Open
|
April 19, 2024
A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations
J Rodon, E Rodriguez, M L Maitland, et al.
Journal of Medicinal Chemistry
|
November 14, 1997
Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity
D M Benbrook, M M Madler, L W Spruce, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 18, 2017
Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer
Efrat Dotan, Steven J Cohen, Alexander N Starodub, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 29, 2009
NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors
Orlo H Clark, Al B Benson, Jordan D Berlin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 16, 2022
Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma
Martin Schuler, Lisa Zimmer, Kevin B Kim, et al.
The Oncologist
|
March 19, 2017
Academic Cancer Center Phase I Program Development
Arthur E Frankel, Keith T Flaherty, George J Weiner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 6, 2009
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008
C Verslype, E Van Cutsem, M Dicato, et al.
The Oncologist
|
May 7, 2014
Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel
Douglas B Johnson, Kimberly H Dahlman, Jared Knol, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 20, 2021
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
A Bardia, W A Messersmith, E A Kio, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 30, 2010
Pancreatic adenocarcinoma
Margaret A Tempero, J Pablo Arnoletti, Stephen Behrman, et al.
Page
of 25